Navigation Links
Enrollment Begins on Human PK Study for Medidur(TM) FA
Date:8/22/2007

ATLANTA, Aug. 22 /PRNewswire-FirstCall/ -- Alimera Sciences, a privately held ophthalmic pharmaceutical company, and pSivida Limited (Nasdaq: PSDV, ASX: PSD, Xetra: PSI) today announced that enrollment has begun for the first human pharmacokinetic (PK) study of fluocinolone acetonide (FA) in Medidur(TM), the companies' investigational product for the treatment of diabetic macular edema (DME).

Medidur is a tiny insert, injected intra-vitreally during an in-office procedure, which is being studied as a way to deliver a very low dose of fluocinolone acetonide (FA), a corticosteroid, to the retina for up to three years as a treatment for DME. Medidur FA is currently in a Phase III global clinical trial, the FAME(TM) (Fluocinolone Acetonide in Diabetic Macular Edema) Study that will follow approximately 900 patients in the U.S., Canada, Europe and India for three years with safety and efficacy assessed at two years. Enrollment for this study has currently exceeded 750 patients.

This PK study is designed to support the FAME trial by providing pharmacokinetic/pharmacodynamic correlation data from DME patients. Sixteen patients are planned to be enrolled in this three-year, open label study. Samples of blood and aqueous humor (the fluid in the front of the eye) will be periodically taken to assess systemic and anterior chamber drug levels, respectively.

"Enrolling the same population in this study as in our FAME trial for DME will provide another important opportunity to learn more about the effect of FA on various aspects of this condition, as well as assess systemic drug levels," said Ken Green, PhD, Chief Scientific Officer for Alimera. "This study will also provide information on the location of Medidur
'/>"/>

SOURCE Alimera Sciences Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
2. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
3. Celsion Completes Enrollment in Phase I Liver Cancer Study
4. Testing for Human Papillomavirus
5. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells
6. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
7. Apollos human proteins boost stem cell research
8. Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo
9. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
10. Second Successful Quigley QR-443 Study Suggests Method of Action Relevant to Broad Range of Chronic Inflammatory Diseases - Human Study to Follow -
11. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... -- Research and Markets  has announced the addition of ... report to their offering. ... drug market has been expanding rapidly owing to the ... During 2005-2013, sales of recombinant protein drugs available in ... and it is projected that China ...
(Date:11/21/2014)... 21, 2014  Alere Inc. (NYSE: ALR ... appointed Juliet Cunningham as Vice President, Investor ... responsible for driving communications with the investment community. ... of changes to increase shareholder value, it is critical ... Namal Nawana, Chief Executive Officer. "We are delighted that ...
(Date:11/21/2014)... and VIENNA, Va. , Nov. ... care provider that operates in Southern California ... provider of remote caregiving technology. Alta will be providing ... client receiving homecare services. Logo - ... is the key to providing the kind of affordable ...
Breaking Medicine Technology:China Recombinant Protein Drug Industry Report, 2014-2017 2China Recombinant Protein Drug Industry Report, 2014-2017 3Alere Appoints Juliet Cunningham to Lead Investor Relations 2Alta Home Care, Inc. and BeClose Partner to Enable Seniors to Remain in Their Homes Safely and Securely 2
... Two Large Phase III Trials Confirm Robust Efficacy ... announced today the results of new,Phase III data ... at the American,College of Rheumatology Annual Scientific Meeting ... only PEGylated Fc-free,anti-TNF (Tumor Necrosis Factor), given with ...
... imatinib,mesylate, more commonly known as Gleevec(R), proves safe and ... form of chronic myeloid leukemia,(CML), according to a study ... Society of Hematology., A team of researchers from ... MD, followed 454 patients with chronic-phase CML,taking imatinib for ...
Cached Medicine Technology:CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 2CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 3CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 4CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 5CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 6CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 7CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year 8Leukemia Drug Proves Safe and Effective Over the Long Term 2
(Date:11/22/2014)... 2014 A new AlignLife Chiropractic & ... the downtown Greenville area. Dr. Chelsea Sineath, owner and ... to open her own clinic after working in another ... patients. , AlignLife believes that the body can ... focus on chiropractic care and rehabilitation to allow the ...
(Date:11/22/2014)... November 23, 2014 Recently, UWDress.com, a successful ... formal wedding guest attire in order to prepare for ... prices, up to 70% off. , UWDress.com is a ... are very beautiful, especially the new items -- formal wedding ... in the current market, including superstar and princess. As one ...
(Date:11/22/2014)... November 23, 2014 BambooFlooringChina.com is ... company has proudly released its new collection of bamboo ... rates, up to 29% off. , According to ... sturdy tree-like grass, making it a highly renewable resource. Their ... have a mixing color which comes from natural bamboo with ...
(Date:11/22/2014)... (PRWEB) November 22, 2014 “Due to my ... an inventor, from Gurnee, Ill. “While using the ice grip ... and I thought there needed to be a safer way ... the SPIKE BLOCK. , The SPIKE BLOCK offers added safety ... it would help to reduce injuries and damage associated with ...
(Date:11/22/2014)... Nocturia is defined by the International ... individual has to wake at night one or ... Pipeline Review, H2 2014” provides comprehensive information on ... analysis at various stages, therapeutics assessment by drug ... (RoA) and molecule type, along with latest updates, ...
Breaking Medicine News(10 mins):Health News:AlignLife of Downtown Greenville is Now Open and Accepting New Patients 2Health News:Formal Wedding Guest Attire Added to UWDress.com 2Health News:Trendy Bamboo Mats Online Now By BambooFlooringChina.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 2Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 3Health News:Nocturia Therapeutic Pipeline Market Review by Drugs and Companies H2 2014 Report at RnRMarketResearch.com 4
... June 28 (HealthDay News) -- The time it takes ... emergency coronary angioplasty was greatly reduced when a statewide ... study finds. It included 436 patients with ST-elevation ... attack that occurs when a large area of the ...
... international team of researchers says abortion stigma is under-researched, ... who,ve had abortions. As a result, they,re launching a ... surrounding abortion. Their invited paper, "Abortion Stigma: ... in the current journal, Women,s Health Issues ...
... TUESDAY, June 28 (HealthDay News) -- Many members of low-income ... new study shows. In assessing the families, eating patterns ... that more than 70 percent of the 100 families, who ... to consume adequate amounts of several vital nutrients, including vitamins ...
... of scheduling chemotherapy treatments has been substantially reduced by a ... from the Sauder School of Business at the University of ... Called Chemo SmartBook, the innovative new scheduling system ... from the Health Employers Association of British Columbia in the ...
... , TUESDAY, June 28 (HealthDay News) -- ,A new study ... risk of death from heart disease than whites: Blacks appear to ... up in arteries and is not detected in standard screening. ... accumulate deep in the walls of arteries -- can rupture and ...
... many years against allergic rhinitis. Still, there has been ... seasonal allergic rhinitis (hay fever), particularly in children. Now, ... of Plant and Environmental Sciences at the University of ... of seasonal allergic rhinitis in children, without any adverse ...
Cached Medicine News:Health News:Program Shrinks Time-to-Treatment for Heart Attack: Study 2Health News:International team explores the stigma surrounding abortion 2Health News:Low-Income Families Often Miss Out on Proper Nutrition 2Health News:Innovative UBC-BC Cancer Agency system reduces waitlisting for chemotherapy patients 2Health News:Innovative UBC-BC Cancer Agency system reduces waitlisting for chemotherapy patients 3Health News:Study Hints at Why Heart Disease Is More Deadly for Blacks 2Health News:Children's hay fever relieved by cellulose power without adverse effects 2
... a unique wrap around design which fits ... for optimum coverage. The ratchet style ... up and down for a comfortable fit. ... to the Model #67, however, the ultra-lite ...
A soft vinyl goggle with limited splash protection due to its contoured facial fit. With leaded side shields added for increased scatter radiation protection. The mask easily fits over existing glass...
... wrap frame is constructed of extremely durable ... potential breakage. The molded wrap around ... saddle bridge to distribute weight evenly over ... with leaded glass side shields. Also ...
All New Ultra Pb Series Glasses...
Medicine Products: